Bipolar Disorder
A lifelong mood disorder marked by severe highs (mania) and lows (depression), treated primarily with mood stabilizers like Lithium or Valproate.
Emergency Management: Acute suicidal ideation with intent/plan or severe acute mania with agitation/psychosis requires immediate psychiatric hospitalization, often involuntary, and rapid chemical tranquilization (e.g., IM Haloperidol and Lorazepam).
Bipolar disorder is a severe, chronic psychiatric illness characterized by extreme shifts in mood, energy, and activity levels. Patients experience alternating, distinct episodes of elevated or irritable mood (mania or hypomania) and episodes of profound sadness and hopelessness (major depression). These mood fluctuations significantly impair interpersonal, occupational, and social functioning.
Detailed Overview
The disorder is subclassified primarily into Bipolar I (characterized by at least one full manic episode, often with major depressive episodes) and Bipolar II (characterized by major depressive episodes and at least one hypomanic episode, without full mania). The cycling between mood states can be rapid or separated by years of euthymia. Suicide risk is exceptionally high, particularly during depressive episodes or mixed states. Treatment is lifelong, centered on mood-stabilizing medications to prevent acute episodes, combined with psychotherapy. Antidepressant monotherapy is heavily contraindicated as it can precipitate manic switches.
Epidemiology & Demographics
The global lifetime prevalence is roughly 1-2% for Bipolar I and 1% for Bipolar II. The average age of onset is 20-25 years. It affects males and females equally, though females are more likely to experience rapid cycling and mixed states. High rates of psychiatric comorbidities, notably substance use disorders and anxiety disorders, are observed.
Etiological Mechanism
A highly heritable condition (heritability ~80%). It involves complex interactions between multiple genetic loci (e.g., genes governing calcium channels like CACNA1C) and environmental triggers, such as severe stress, sleep deprivation, or substance use.
Primary Causes
No single cause exists. Pathogenesis is driven by genetic susceptibility, dysregulation of monoamine neurotransmitters (dopamine, serotonin, norepinephrine), intracellular signaling abnormalities (e.g., protein kinase C, inositol depletion), and structural/functional brain abnormalities in the prefrontal cortex and amygdala.
The exact pathophysiology is not fully elucidated. The 'monoamine hypothesis' suggests that mania is associated with an excess of catecholamines (dopamine and norepinephrine), while depression relates to a deficit. More recent theories focus on disrupted intracellular signaling pathways. For example, overactivity of the phosphatidylinositol (PI) cycle and protein kinase C (PKC) are implicated in mania; lithium directly inhibits inositol monophosphatase, dampening this overactive signaling. Structural imaging shows volume reductions in the prefrontal cortex and hippocampus, alongside amygdala hyperactivity, reflecting impaired regulation of emotional responses.
Diagnostic Criteria & Guidelines
Diagnosis is based on DSM-5 criteria. For Bipolar I: At least one manic episode lasting >= 1 week (or any duration if hospitalized), presenting with abnormally elevated or irritable mood and increased energy, plus 3+ symptoms (grandiosity, decreased sleep, pressured speech, flight of ideas, distractibility, increased goal-directed activity, risky behavior). Bipolar II requires at least one hypomanic episode (>= 4 days) and at least one major depressive episode, with no history of full mania.
Acute Mania: Lithium 300 mg PO BID-TID titrated to serum levels, OR Valproic Acid 15-20 mg/kg/day PO, OR Second-generation Antipsychotics (e.g., Quetiapine, Olanzapine, Aripiprazole). Severe episodes may require a combination of Lithium/Valproate + an Antipsychotic. Bipolar Depression: Quetiapine 300 mg PO daily, Lurasidone 20-120 mg PO daily, or Cariprazine.
Second-Line & Adjunctive Therapy
Maintenance/Prophylaxis: Lamotrigine is highly effective for preventing depressive relapse (slowly titrated to 200 mg/day to avoid Stevens-Johnson Syndrome). Carbamazepine or Oxcarbazepine are alternatives for mood stabilization. Electroconvulsive Therapy (ECT) is highly effective for treatment-resistant mania or depression, or when rapid response is needed (e.g., severe suicidality, catatonia).
Surgical & Procedural Management
Not applicable. Vagus Nerve Stimulation (VNS) or Transcranial Magnetic Stimulation (TMS) are sometimes used off-label for severe, refractory bipolar depression.
Patient Counseling & Advice
Emphasize that bipolar disorder is a chronic condition requiring lifelong medication adherence, even during euthymic periods, to prevent relapse. Educate the patient and family on recognizing early warning signs (prodrome) of impending episodes, particularly decreased need for sleep. Warn explicitly against stopping medications abruptly or taking unprescribed antidepressants.
Follow-Up & Monitoring Schedule
Psychiatric visits every 1-3 months during maintenance. Routine lab monitoring: for Lithium (Renal function, TSH, serum lithium levels), for Valproate/Carbamazepine (LFTs, CBC, serum levels), and for atypical antipsychotics (fasting lipids, HbA1c, weight).
Preventive Strategies
Secondary prevention focuses on medication adherence and avoiding triggers (sleep deprivation, substances). Interpersonal and Social Rhythm Therapy (IPSRT) is an evidence-based psychotherapy that helps stabilize daily routines.
Highly variable. While many patients achieve functional recovery with proper treatment, relapses are common (up to 70% relapse within 5 years). Morbidity is heavily influenced by medication adherence and the presence of comorbid substance use.